Loading company
Latest annual · FY2021
Millions- Total revenues
- 18
- Operating income
- (23)
- Net income
- (22)
- Free cash flow
- (20)
Latest quarter · Q1 FY2024
Millions- Operating income
- (9)
- Net income
- (9)
- Free cash flow
- (5)
Landos Biopharma, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$22.7 million | -$40.6 million | 10-K 2024-03-21 · proof | |
| Net income | -$21.9 million | -$39.3 million | 10-K 2024-03-21 · proof | |
| Cash from operating activities | -$20.5 million | -$45.8 million | 10-K 2024-03-21 · proof | |
| Free cash flow | -$20.5 million | -$45.8 million | 10-K 2024-03-21 · proof | |
| Total assets | $38 million | $45.3 million | -15.9% | 10-K 2024-03-21 · proof |
| Total liabilities | $6.2 million | $6.1 million | +2.1% | 10-K 2024-03-21 · proof |
| Cash and cash equivalents | $37.5 million | $36.6 million | +2.3% | 10-K 2024-03-21 · proof |
- What was Landos Biopharma, Inc.'s operating income in fiscal 2023?
- Landos Biopharma, Inc. reported operating income of -$22.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$40.6 million the year before. Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What was Landos Biopharma, Inc.'s net income in fiscal 2023?
- Landos Biopharma, Inc. reported net income of -$21.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$39.3 million the year before. Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What was Landos Biopharma, Inc.'s cash from operating activities in fiscal 2023?
- Landos Biopharma, Inc. reported cash from operating activities of -$20.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$45.8 million the year before. Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What was Landos Biopharma, Inc.'s free cash flow in fiscal 2023?
- Landos Biopharma, Inc. reported free cash flow of -$20.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$45.8 million the year before. Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What are Landos Biopharma, Inc.'s total assets?
- As of Dec 31, 2023, Landos Biopharma, Inc. reported total assets of $38 million, against $45.3 million a year earlier (-15.9%). Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What are Landos Biopharma, Inc.'s total liabilities?
- As of Dec 31, 2023, Landos Biopharma, Inc. reported total liabilities of $6.2 million, against $6.1 million a year earlier (+2.1%). Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
- What are Landos Biopharma, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Landos Biopharma, Inc. reported cash and cash equivalents of $37.5 million, against $36.6 million a year earlier (+2.3%). Source: the 10-K filed with the SEC on Mar 21, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1785345&period_type=annual&limit=5"Information only, not investment advice.